Intrommune Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Intrommune Therapeutics's estimated annual revenue is currently $3.1M per year.(i)
  • Intrommune Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Intrommune Therapeutics has 20 Employees.(i)
  • Intrommune Therapeutics grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M7250%N/AN/A
#2
$5.9M3815%N/AN/A
#3
$34.7M2246%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.9M6-14%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$4.2M27-16%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

Intrommune Therapeutics is a specialty biopharmaceutical company located in New York, NY. Intrommune is developing a revolutionary new treatment platform for food allergies that is safe, effective and convenient. Intrommune's first product is a therapy for patients who suffer from peanut allergy. Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 9 million U.S. adults and 6 million U.S. children, who suffer from this life-altering condition.

keywords:N/A

N/A

Total Funding

20

Number of Employees

$3.1M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Intrommune Therapeutics News

2022-03-30 - INT301 Continues to Meet Safety Goals in Phase 1 OMEGA ...

Intrommune Expands Study Scope to Explore MTD. NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.1M20-46%$25.1M
#2
$2M2018%N/A
#3
$2M20-20%N/A
#4
$3.5M20-46%N/A
#5
$3.1M20-17%N/A